ClinicalTrials.gg
CompletedNCT03007433Updated Jan 2, 2017

Assessment of GI Function to a Large Test Meal by Non-invasive Imaging

An interventional study of 400ml of Liquid Nutrient Drink in Functional Dyspepsia, sponsored by Nottingham University Hospitals NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-02.

Sponsored by Nottingham University Hospitals NHS Trust · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Dyspeptic symptoms such as abdominal pain, bloating and nausea after a meal are common; however the cause of these problems in many patients is often unclear despite medical investigation. This is because "dyspeptic symptoms" are only rarely related to acid reflux, stomach ulcers or cancer that can be diagnosed by endoscopy. Rather, the cause is abnormal stomach function, so-called "functional dyspepsia", a condition in which the digestive system does not function normally after a meal. Gastric scintigraphy is the standard investigation of stomach function in patients with this condition. It involves eating a small test meal that includes a tiny dose of radioactive material so that the movement of food can be visualised as it empties from the stomach. An important limitation of this approach is that symptoms are rarely caused and delayed emptying after a small meal is present only in a minority of patients and, thus, the ability of this investigation to explain the cause of symptoms or guide medical treatment is limited.

This research project is designed to compare three new investigations of stomach function using a relatively large meal. This information will help to explain the causes of symptoms after a meal. The investigations to be tested include: (1) Nutrient Drink Test, (2) Gastric Scintigraphy and (3) Magnetic Resonance Imaging. All three tests are safe, easy to perform and non-invasive (i.e. do not involve inserting catheters through the nose and into the stomach or taking blood). The results should provide more useful information to doctors looking after patients with dyspeptic symptoms.

This study will compare test results from healthy volunteers, with patients attending clinic for investigation of dyspeptic symptoms. The aim is to document abnormal function of the stomach and intestines and to identify the causes of dyspeptic symptoms after a meal.

Read the detailed description

The Nutrient Drinking Test will be performed as part of the screening visit to ensure that all patients that consent to participate in the full study are able to complete the imaging studies that require ingestion of 400ml liquid nutrient (Fortisip Vanilla (Nutricia Clinical) diluted 1:1 with water to 0.75kcal/ml, 4.5g fat/100ml).

Subjects will drink one from a series of beakers containing 40ml liquid nutrient every minute. During the drinking test, subjects will score satiety, fullness, bloating, heartburn, nausea and epigastric pain at 5-min intervals using a 100mm visual analogue scale (sample attached). Participants will be instructed to cease intake when they reported maximal satiety or very severe dyspeptic symptoms (defined as VAS score of >90 mm). The total volume ingested will be recorded. Symptoms will be assessed again 15 and 30 min after cessation of intake.

If the subject fulfils the inclusion and exclusion criteria including ingestion of ≥400ml at the drinking test and consents to continue then appointments will be made for gamma scintigraphy and MRI studies according to a prospective randomization plan.

MRI Study Day After eligibility has been confirmed subjects will ingest the paramagnetic contrast labelled liquid nutrient test meal according to a standardized protocol. Subjects will drink one from a series of ten beakers containing 40ml liquid nutrient every minute. During the test meal, subjects will score satiety, fullness, bloating, heartburn, nausea and epigastric pain at baseline, 5 and 10 minute using a visual analogue scale (VAS 0-100 mm). These measurements will be repeated at 30min and at the conclusion of the imaging study (see below).

Studies will be performed using a 1.5T whole MRI system (Intera, Philips, Best, The Netherlands). Six rectangular surface coils (height = 20 cm, width = 10 cm), fixed around the abdomen and connected to independent receive channels were used for signal detection.

Gamma Scintigraphy Study Day After eligibility has been confirmed subjects will ingest the radiolabelled liquid nutrient test meal according to a standardized protocol. Subjects will drink one from a series of ten beakers containing 40ml liquid nutrient every minute. During the test meal, subjects will score satiety, fullness, bloating, heartburn, nausea and epigastric pain at baseline, 5 and 10 min using a visual analogue scale (VAS 0-100 mm).

02

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • gastric emptying
  • functional dyspepsia
  • non invasive imaging
  • MRI
  • gamma scintigraphy
  • gastroparesis
03

In context

Gastroparesis

311 studies on the registry are indexed under Gastroparesis; 67 are open to participants now.

This study's enrollment of 61 is above the median of 42 across 205 interventional studies indexed under Gastroparesis.

Browse Gastroparesis studies →

Lead sponsor

Nottingham University Hospitals NHS Trust is the lead sponsor of 107 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be an adult patient above 18 years old
  • Meet the block randomization criteria for age and sex (no such allocation required for patient group)
  • Have a body mass index of >18 and \<30kg.m2 and not exceed a waist circumference of 99cm at 5cm above ileal crest
  • Be able to give voluntary informed consent and from whom written consent to participate has been obtained.
  • Be able to understand the study, willing to co-operate with the study procedures and able to attend all study assessments.
  • Be willing to abstain from alcohol for 24 hours before and during the imaging appointment.
  • Be willing to fast from midnight prior to the screening and imaging appointment
  • Be able to ingest at least 400ml nutrient liquid (0.75kcal/ml at 40ml/min) during a Nutrient Drinking Test without experiencing more than moderate dyspeptic symptoms (no such restriction for patients with dyspeptic symptoms)
  • Be willing to consent to their General Practitioner (GP) being informed of their participation.

Exclusion criteria

Exclusion Criteria:

  • Have a history of gastrointestinal disease or surgery (other than appendicitis or hysterectomy)
  • Have ongoing disease requiring active management
  • Have a documented history of alcohol or drug abuse
  • Fail to satisfy the investigator's assessment of fitness to participate based on a survey of inclusion and exclusion criteria
  • Have consumed alcohol within 24 hours of start of study
  • Have participated in a similar study involving the use of radioisotopes in the previous 3 months such that participating in the current study would exceed the recommended yearly exposure limit (5mSv)
  • Take any medication which may affect oesophageal or gastric motility for a minimum 7 days
  • Have had previous history of gastric surgery
  • Have active upper gastrointestinal diseases
  • Have an active Eating Disorder
  • Have an allergy to milk protein (milk based, lactose free test meal)
  • Be a vegan
  • Be pregnant or breastfeeding
  • Have any contraindication to MRI scanning according to local guidelines
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    healthy volunteers

    60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (\<40, 41-60, \>60) are recruited.

    Other: 400ml of Liquid Nutrient Drink

  • Experimental
    Functional dyspeptic patients

    20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population

    Other: 400ml of Liquid Nutrient Drink

Interventions

  • Other400ml of Liquid Nutrient Drink

    12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)

    Also known as: Fortisip Vanilla

06

What researchers measure

Primary outcomes

  1. Assessment of gastric sensory function using the nutrient drink test for volume ingested at maximum satiation

    Time frame: 4 months from consent

  2. Estimate steady state gastric emptying rate (ml/min) using Gamma Scintigraphy And Magnetic Resonance Imaging (MRI)

    Time frame: 4 months from consent

07

Study locations

1 site
  • Nottingham University Hopsitals
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Jan 2, 2017
Start
Oct 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Jan 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03007433
Responsible party
Sponsor
First posted
Jan 2, 2017
Start date
Oct 2010
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Jan 2, 2017

Study contacts

Mark R Fox, MD
principal investigator · Univeristy Hopsitals Nottingham

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion